Related Experiment Video
Updated: Jan 2, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells
Margalida Torrens-Mas1, Marco Cordani2, Nidula Mullappilly3
1Grupo Multidisciplinar de Oncología Traslacional, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears (UIB), Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma, Spain.
Abstract:
The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 isoforms can acquire oncogenic properties referred to as gain-of-function (GOF). In this study, we used wild-type (A375) and mutant p53 (MeWo) melanoma cell lines to assess the regulation of the mitochondrial antioxidant manganese superoxide dismutase (MnSOD) by mutant p53. The effects of mutant p53 were evaluated by qPCR, immunoblotting, enzyme activity assay, cell proliferation assay, reactive oxygen species (ROS) assay after cellular transfection. We demonstrate that mutant p53 induces MnSOD expression, which is recovered by the ROS scavenger N-acetyl-l-cysteine. This suggests MnSOD induction as a defense mechanism of melanoma cells to counterbalance the pro-oxidant conditions induced by mutant p53. We also demonstrate that mutant p53 induces the expression of Sirtuin3 (SIRT3), a major mitochondrial NAD+-dependent deacetylase, stimulating MnSOD deacetylation and enzymatic activity. Indeed, the restoration of SIRT3 reverses MnSOD activity decrease by mutant p53 knock-down. Finally, MnSOD knock-down further enhances mutant p53-mediated ROS increase, counteracting mutp53-dependent cell hyperproliferation. This indicates that SIRT3 and MnSOD act to maintain ROS levels controlled to promote cell proliferation and survival, providing new therapeutic opportunities to be further considered for clinical studies in cancer patients bearing mutant TP53 gene.
Insights
Mutant TP53 in melanoma cells boosts manganese superoxide dismutase (MnSOD) and Sirtuin3 (SIRT3) to manage reactive oxygen species (ROS), promoting cancer cell proliferation and survival.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The TP53 tumor suppressor gene is frequently altered in cancer.
- Mutant p53 isoforms can gain oncogenic, gain-of-function (GOF) properties.
- Melanoma cells with mutant p53 exhibit altered cellular processes.
Purpose of the Study:
- To investigate how mutant p53 regulates manganese superoxide dismutase (MnSOD) in melanoma.
- To explore the role of mutant p53 in controlling reactive oxygen species (ROS) levels.
- To identify potential therapeutic targets in mutant TP53-driven cancers.
Main Methods:
- Utilized wild-type and mutant p53 melanoma cell lines (A375, MeWo).
- Employed quantitative PCR (qPCR), immunoblotting, and enzyme activity assays.
- Assessed cell proliferation, ROS levels, and effects of transfection and knockdown.
Main Results:
- Mutant p53 induces MnSOD expression, a response counteracted by ROS scavengers.
- Mutant p53 upregulates Sirtuin3 (SIRT3), enhancing MnSOD deacetylation and activity.
- SIRT3 and MnSOD maintain controlled ROS levels, supporting melanoma cell proliferation and survival.
Conclusions:
- Mutant p53 utilizes the SIRT3-MnSOD pathway to manage ROS, promoting cancer progression.
- This pathway represents a critical mechanism for melanoma cell survival and proliferation.
- Targeting the SIRT3-MnSOD axis offers potential therapeutic strategies for mutant TP53 cancers.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules

